POAI
Predictive Oncology Inc
$
0.916
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.920
Open
0.900
VWAP
0.90
Vol
59.66K
Mkt Cap
9.98M
Low
0.87001
Amount
53.78K
EV/EBITDA(TTM)
--
Total Shares
4.10M
EV
9.56M
EV/OCF(TTM)
--
P/S(TTM)
3.96
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Show More
Valuation Metrics
The current forward P/E ratio for Predictive Oncology Inc (POAI.O) is -10.59, compared to its 5-year average forward P/E of -3.38. For a more detailed relative valuation and DCF analysis to assess Predictive Oncology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.38
Current PE
-10.59
Overvalued PE
-0.21
Undervalued PE
-6.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.26
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.41
Undervalued EV/EBITDA
-3.93
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
8.56
Current PS
0.90
Overvalued PS
18.44
Undervalued PS
-1.32
Financials
Annual
Quarterly
FY2025Q2
YoY :
-99.04%
2.68K
Total Revenue
FY2025Q2
YoY :
-16.60%
-2.66M
Operating Profit
FY2025Q2
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q2
YoY :
-66.18%
-0.23
EPS - Diluted
FY2025Q2
YoY :
+2.18%
-3.29M
Free Cash Flow
FY2025Q2
YoY :
-1384.09%
-579.38
Gross Profit Margin - %
FY2025Q2
YoY :
+18.65%
-830.20
FCF Margin - %
FY2025Q2
YoY :
+6364.54%
-73.78K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
POAI News & Events
Events Timeline
2025-08-14 (ET)
2025-08-14
07:11:51
Predictive Oncology reports Q2 EPS (22c) vs. (53c) last year
2025-07-15 (ET)
2025-07-15
09:07:09
Predictive Oncology issues letter to shareholders
2025-07-08 (ET)
2025-07-08
09:04:25
Predictive Oncology enters standby equity purchase agreement with Yorkville
Sign Up For More Events
Sign Up For More Events
News
8.5
08-19GlobenewswireInvestor Alert from Former Louisiana Attorney General: Kahn Swick & Foti, LLC Examines Price and Process in Predictive Oncology Inc. (POAI) Proposed Sale
9.5
08-14NASDAQ.COMPOAI Reports Earnings
8.5
07-21SeekingAlphaPredictive Oncology files to sell 1.92M shares of common stock for holders
Sign Up For More News
People Also Watch
MGRX
Mangoceuticals Inc
1.660
USD
+9.57%
SLE
Super League Enterprise Inc
3.280
USD
-0.61%
IBG
Innovation Beverage Group Ltd
0.570
USD
+0.18%
GMM
Global Mofy AI Ltd
2.330
USD
-0.43%
FGI
FGI Industries Ltd
3.760
USD
0.00%
ALUR
Allurion Technologies Inc
1.990
USD
-6.57%
LDWY
Lendway Inc
5.150
USD
+1.98%
OMH
Ohmyhome Ltd
1.160
USD
0.00%
ROMA
Roma Green Finance Ltd
2.715
USD
+4.83%
FAQ
What is Predictive Oncology Inc (POAI) stock price today?
The current price of POAI is 0.916 USD — it has increased 1.78 % in the last trading day.
What is Predictive Oncology Inc (POAI)'s business?
What is the price predicton of POAI Stock?
What is Predictive Oncology Inc (POAI)'s revenue for the last quarter?
What is Predictive Oncology Inc (POAI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Predictive Oncology Inc (POAI)'s fundamentals?
How many employees does Predictive Oncology Inc (POAI). have?